Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy

Journal of Infectious Diseases

Volumn 183, Issue 5, 2001, Pages 722-729

  Seth, Aruna ^a   Markee, Janan ^c   Hoering, Antje ^c   Sevin, Anne ^b   Sabath, Daniel E ^c   Schmitz, J�rn E ^a   Kuroda, Marcelo J ^a   Lifton, Michelle A ^a   Hirsch, Martin S ^a   Collier, Ann C ^c   Letvin, Norman L ^a   McElrath, M Juliana ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD8 ANTIGEN; EPITOPE; FAS ANTIGEN; HLA A ANTIGEN; INDINAVIR; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PHENOTYPE; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIGENS, CD45; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HLA-DR ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INDINAVIR; LAMIVUDINE; PROSPECTIVE STUDIES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD; ZIDOVUDINE;

EID: 0035282636     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/318816     Document Type: Article

References (28)

1. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodefciency virus type 1 syndrome
2. Envelope cytotoxic T cell responses correlate with viral load and disease progression in early HIV-1 infection
3. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA
4. Antiviral pressure exerted by HIV-1 specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
5. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
6. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progresssors and long-term asymptomatics
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
9. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
10. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
11. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
12. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
13. − T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
14. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
15. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
16. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis
17. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization
18. IL-15 stimulates the expansion of AIDS virus specific CTL
19. + lymphocytes
20. +) T cell depletion in simian immunodeficiency virus-infected macaques
21. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells
22. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
23. Evolution of cytotoxic T lymphocytes response to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
24. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
25. Alterations in the immune response of human inmunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
26. + T cell homeostasis and function in advanced HIV disease
27. + T cells in individuals receiving highly active antiretroviral therapy (HAART)
28. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy